Biotechnology Assets, S.A.

BST

ES0184980003

Biotechnology & Medical Research

Delayed BME Other stock markets 15:45:54 20/05/2024 BST			5-day change	1st Jan Change
0.3445 ^EUR	+1.32%		-1.29%	-13.01%

04-05	Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt	CI

ADL Bionatur Solutions, S.A. Provides Sales Guidance for 2019

August 07, 2019 at 08:15 am

ADL Bionatur Solutions, S.A. provided sales guidance for 2019. For the year, the company expects revenues between EUR 50 to EUR 55 million.

Latest news about Biotechnology Assets, S.A.

Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	04-04	CI
Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt	10/04/23	CI
Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	10/04/23	CI
Biotechnology Assets, S.A. Auditor Raises 'Going Concern' Doubt	12/04/22	CI
Biotechnology Assets, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	12/04/22	CI
ADL Bionatur Solutions, S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	29/10/21	CI
ADL Bionatur Solutions, S.A. announced that it has received ?12 million in funding from Kartesia Advisor LLP	19/10/21	CI
Adl Bionatur Solutions, S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	11/05/21	CI
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt	10/05/21	CI
ADL Bionatur Solutions, S.A. announced that it expects to receive €5 million in funding	18/03/21	CI
ADL Bionatur Solutions, S.A. announced that it has received €12 million in funding from Kartesia Advisor LLP	25/02/21	CI
Kartesia Advisor LLP acquired 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. and Black Toro Capital LLP.	06/10/20	CI
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt	21/06/20	CI
ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million	02/12/19	CI
ADL Bionatur Solutions Announces Revenue Results for the Third Quarter and Nine Months of 2019; Confirms Revenue Guidance for the Full Year of 2019	13/11/19	CI
ADL Bionatur Solutions Announces Earnings Results for the First Six Months of 2019; Provides Guidance for the Full Year 2019	10/10/19	CI
ADL Bionatur Solutions, S.A. announced that it has received €25 million in funding from Kartesia Advisor LLP	11/08/19	CI
ADL Bionatur Solutions, S.A. Provides Sales Guidance for 2019	07/08/19	CI
ADL Bionatur Solutions Enters into an Initial EUR 13 Million Strategic Alliance with Japanese Pharma Company	07/08/19	CI
ADL Bionatur Solutions and Amyris, Inc. Expand Contract to 2020	22/07/19	CI
ADL Bionatur Solutions Increases 2019 Production for Global Nutrition Company for Additional Revenues of over EUR 2.5 Million	09/07/19	CI
ADL Bionatur Solutions, S.A. Provides Sales Guidance for 2019	06/05/19	CI
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt	11/04/19	CI
Nutricion Center NC and ADL Bionatur Solutions Sign Strategic Alliance to Tackle Weight Control by Rebalancing the Gut Microbiome	19/02/19	CI
Amyris and ADL Bionatur Solutions Expand Production Agreement to Meet Growing Demand	10/12/18	CI

Chart Biotechnology Assets, S.A.

Duration

Period

More charts

Biotechnology Assets SA, formerly known as ADL Bionatur Solutions SA, is a Spain-based biotech company. The Firmâs main activities are: Research, development and production of biotechnological solutions aimed at improving the health and welfare of people and animals; Development, acquisition, transfer and exploitation of industrial and intellectual property rights; Distribution, marketing, export and import of the previously mentioned products. The Company, through its subsidiaries, is also present in Luxembourg, Hong Kong and USA.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOTECHNOLOGY ASSETS, S.A.	-13.01%	21.34M
VERTEX PHARMACEUTICALS INCORPORATED	+9.85%	115B
REGENERON PHARMACEUTICALS, INC.	+12.01%	106B
ARGENX SE	-2.91%	21.96B
BIONTECH SE	-13.66%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.61%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+6.56%	14.32B
SAREPTA THERAPEUTICS, INC.	+34.60%	12.42B